APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neuraminidase Inhibitors Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Neuraminidase Inhibitors Drug Market Analysis and Forecast 2026-2032

2 January 2026193 pages

Choose your research edition.

Industry ResearchNeuraminidase Inhibitors Drug Industry Research Report 2026117 pages · $2,950 USDIndustry Growth & TrendsGlobal Neuraminidase Inhibitors Drug Industry Growth and Trends Forecast to 203285 pages · $3,450 USDMarket StructureGlobal Neuraminidase Inhibitors Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neuraminidase Inhibitors Drug Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Neuraminidase Inhibitors Drug Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Neuraminidase Inhibitors Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Neuraminidase Inhibitors Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Neuraminidase Inhibitors Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Neuraminidase Inhibitors Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Neuraminidase Inhibitors Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Neuraminidase Inhibitors Drug include Teva, Roche, Pfizer, GSK, AstraZeneca, Sun Pharmaceutical, Gilead Sciences, Daiichi Sankyo and Bristol-Myers Squibb, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Neuraminidase Inhibitors Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Neuraminidase Inhibitors Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Neuraminidase Inhibitors Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Neuraminidase Inhibitors Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Neuraminidase Inhibitors Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Neuraminidase Inhibitors Drug revenue, projected growth trends, production technology, application and end-user industry.

Neuraminidase Inhibitors Drug Segment by Company

Teva

Roche

Pfizer

GSK

AstraZeneca

Sun Pharmaceutical

Gilead Sciences

Daiichi Sankyo

Bristol-Myers Squibb

Neuraminidase Inhibitors Drug Segment by Type

Oseltamivir

Laninamivir

Peramivir

Zanamivir

Neuraminidase Inhibitors Drug Segment by Application

Hospital Pharmacy

Online Pharmacy

Retail Pharmacy

Others

Neuraminidase Inhibitors Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuraminidase Inhibitors Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neuraminidase Inhibitors Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuraminidase Inhibitors Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Neuraminidase Inhibitors Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Neuraminidase Inhibitors Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neuraminidase Inhibitors Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Neuraminidase Inhibitors Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Oseltamivir Major Player Table 3. Laninamivir Major Player Table 4. Peramivir Major Player Table 5. Zanamivir Major Player Table 6. Global Neuraminidase Inhibitors Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospital Pharmacy Major Player Table 8. Online Pharmacy Major Player Table 9. Retail Pharmacy Major Player Table 10. Others Major Player Table 11. Neuraminidase Inhibitors Drug Industry Trends Table 12. Neuraminidase Inhibitors Drug Industry Drivers Table 13. Neuraminidase Inhibitors Drug Industry Opportunities and Challenges Table 14. Neuraminidase Inhibitors Drug Industry Restraints Table 15. Global Neuraminidase Inhibitors Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Neuraminidase Inhibitors Drug Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Neuraminidase Inhibitors Drug Market Share by Region (2021-2026) Table 18. Global Neuraminidase Inhibitors Drug Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Neuraminidase Inhibitors Drug Market Share by Region (2027-2032) Table 20. Global Neuraminidase Inhibitors Drug Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Neuraminidase Inhibitors Drug Revenue Market Share by Players (2021-2026) Table 22. Global Neuraminidase Inhibitors Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Neuraminidase Inhibitors Drug Key Players Headquarters & Area Served Table 24. Global Neuraminidase Inhibitors Drug Players, Product Type & Application Table 25. Global Neuraminidase Inhibitors Drug Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Neuraminidase Inhibitors Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Neuraminidase Inhibitors Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Neuraminidase Inhibitors Drug Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Neuraminidase Inhibitors Drug Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Neuraminidase Inhibitors Drug Revenue Market Share by Type (2021-2026) Table 32. Global Neuraminidase Inhibitors Drug Revenue Market Share by Type (2027-2032) Table 33. Global Neuraminidase Inhibitors Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Neuraminidase Inhibitors Drug Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Neuraminidase Inhibitors Drug Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Neuraminidase Inhibitors Drug Revenue Market Share by Application (2021-2026) Table 37. Global Neuraminidase Inhibitors Drug Revenue Market Share by Application (2027-2032) Table 38. Teva Company Information Table 39. Teva Business Overview Table 40. Teva Neuraminidase Inhibitors Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Teva Neuraminidase Inhibitors Drug Product Portfolio Table 42. Teva Recent Development Table 43. Roche Company Information Table 44. Roche Business Overview Table 45. Roche Neuraminidase Inhibitors Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Roche Neuraminidase Inhibitors Drug Product Portfolio Table 47. Roche Recent Development Table 48. Pfizer Company Information Table 49. Pfizer Business Overview Table 50. Pfizer Neuraminidase Inhibitors Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Pfizer Neuraminidase Inhibitors Drug Product Portfolio Table 52. Pfizer Recent Development Table 53. GSK Company Information Table 54. GSK Business Overview Table 55. GSK Neuraminidase Inhibitors Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. GSK Neuraminidase Inhibitors Drug Product Portfolio Table 57. GSK Recent Development Table 58. AstraZeneca Company Information Table 59. AstraZeneca Business Overview Table 60. AstraZeneca Neuraminidase Inhibitors Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. AstraZeneca Neuraminidase Inhibitors Drug Product Portfolio Table 62. AstraZeneca Recent Development Table 63. Sun Pharmaceutical Company Information Table 64. Sun Pharmaceutical Business Overview Table 65. Sun Pharmaceutical Neuraminidase Inhibitors Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Sun Pharmaceutical Neuraminidase Inhibitors Drug Product Portfolio Table 67. Sun Pharmaceutical Recent Development Table 68. Gilead Sciences Company Information Table 69. Gilead Sciences Business Overview Table 70. Gilead Sciences Neuraminidase Inhibitors Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Gilead Sciences Neuraminidase Inhibitors Drug Product Portfolio Table 72. Gilead Sciences Recent Development Table 73. Daiichi Sankyo Company Information Table 74. Daiichi Sankyo Business Overview Table 75. Daiichi Sankyo Neuraminidase Inhibitors Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Daiichi Sankyo Neuraminidase Inhibitors Drug Product Portfolio Table 77. Daiichi Sankyo Recent Development Table 78. Bristol-Myers Squibb Company Information Table 79. Bristol-Myers Squibb Business Overview Table 80. Bristol-Myers Squibb Neuraminidase Inhibitors Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. Bristol-Myers Squibb Neuraminidase Inhibitors Drug Product Portfolio Table 82. Bristol-Myers Squibb Recent Development Table 83. North America Neuraminidase Inhibitors Drug Revenue by Type (2021-2026) & (US$ Million) Table 84. North America Neuraminidase Inhibitors Drug Revenue by Type (2027-2032) & (US$ Million) Table 85. North America Neuraminidase Inhibitors Drug Revenue by Application (2021-2026) & (US$ Million) Table 86. North America Neuraminidase Inhibitors Drug Revenue by Application (2027-2032) & (US$ Million) Table 87. North America Neuraminidase Inhibitors Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 88. North America Neuraminidase Inhibitors Drug Revenue by Country (2021-2026) & (US$ Million) Table 89. North America Neuraminidase Inhibitors Drug Revenue by Country (US$ Million) & (2027-2032) Table 90. Europe Neuraminidase Inhibitors Drug Revenue by Type (2021-2026) & (US$ Million) Table 91. Europe Neuraminidase Inhibitors Drug Revenue by Type (2027-2032) & (US$ Million) Table 92. Europe Neuraminidase Inhibitors Drug Revenue by Application (2021-2026) & (US$ Million) Table 93. Europe Neuraminidase Inhibitors Drug Revenue by Application (2027-2032) & (US$ Million) Table 94. Europe Neuraminidase Inhibitors Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 95. Europe Neuraminidase Inhibitors Drug Revenue by Country (2021-2026) & (US$ Million) Table 96. Europe Neuraminidase Inhibitors Drug Revenue by Country (US$ Million) & (2027-2032) Table 97. China Neuraminidase Inhibitors Drug Revenue by Type (2021-2026) & (US$ Million) Table 98. China Neuraminidase Inhibitors Drug Revenue by Type (2027-2032) & (US$ Million) Table 99. China Neuraminidase Inhibitors Drug Revenue by Application (2021-2026) & (US$ Million) Table 100. China Neuraminidase Inhibitors Drug Revenue by Application (2027-2032) & (US$ Million) Table 101. Asia Neuraminidase Inhibitors Drug Revenue by Type (2021-2026) & (US$ Million) Table 102. Asia Neuraminidase Inhibitors Drug Revenue by Type (2027-2032) & (US$ Million) Table 103. Asia Neuraminidase Inhibitors Drug Revenue by Application (2021-2026) & (US$ Million) Table 104. Asia Neuraminidase Inhibitors Drug Revenue by Application (2027-2032) & (US$ Million) Table 105. Asia Neuraminidase Inhibitors Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 106. Asia Neuraminidase Inhibitors Drug Revenue by Region (US$ Million) & (2021-2026) Table 107. Asia Neuraminidase Inhibitors Drug Revenue by Region (US$ Million) & (2027-2032) Table 108. SAMEA Neuraminidase Inhibitors Drug Revenue by Type (2021-2026) & (US$ Million) Table 109. SAMEA Neuraminidase Inhibitors Drug Revenue by Type (2027-2032) & (US$ Million) Table 110. SAMEA Neuraminidase Inhibitors Drug Revenue by Application (2021-2026) & (US$ Million) Table 111. SAMEA Neuraminidase Inhibitors Drug Revenue by Application (2027-2032) & (US$ Million) Table 112. SAMEA Neuraminidase Inhibitors Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 113. SAMEA Neuraminidase Inhibitors Drug Revenue by Country (2021-2026) & (US$ Million) Table 114. SAMEA Neuraminidase Inhibitors Drug Revenue by Country (US$ Million) & (2027-2032) Table 115. Research Programs/Design for This Report Table 116. Authors List of This Report Table 117. Secondary Sources Table 118. Primary Sources List of Figures Figure 1. Neuraminidase Inhibitors Drug Image Figure 2. Global Neuraminidase Inhibitors Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neuraminidase Inhibitors Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Oseltamivir Image Figure 5. Laninamivir Image Figure 6. Peramivir Image Figure 7. Zanamivir Image Figure 8. Global Neuraminidase Inhibitors Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Neuraminidase Inhibitors Drug Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospital Pharmacy Image Figure 11. Online Pharmacy Image Figure 12. Retail Pharmacy Image Figure 13. Others Image Figure 14. Global Neuraminidase Inhibitors Drug Market Size (US$ Million) & (2021-2032) Figure 15. Global Neuraminidase Inhibitors Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Neuraminidase Inhibitors Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Neuraminidase Inhibitors Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Neuraminidase Inhibitors Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Neuraminidase Inhibitors Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Neuraminidase Inhibitors Drug Revenue Market Share by Type (2021-2032) Figure 22. Global Neuraminidase Inhibitors Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Neuraminidase Inhibitors Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Neuraminidase Inhibitors Drug Revenue Market Share by Application (2021-2032) Figure 25. North America Neuraminidase Inhibitors Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Neuraminidase Inhibitors Drug Revenue Share by Type (2021-2032) Figure 27. North America Neuraminidase Inhibitors Drug Revenue Share by Application (2021-2032) Figure 28. North America Neuraminidase Inhibitors Drug Revenue Share by Country (2021-2032) Figure 29. United States Neuraminidase Inhibitors Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Neuraminidase Inhibitors Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Neuraminidase Inhibitors Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Neuraminidase Inhibitors Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Neuraminidase Inhibitors Drug Revenue Share by Type (2021-2032) Figure 34. Europe Neuraminidase Inhibitors Drug Revenue Share by Application (2021-2032) Figure 35. Europe Neuraminidase Inhibitors Drug Revenue Share by Country (2021-2032) Figure 36. Germany Neuraminidase Inhibitors Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Neuraminidase Inhibitors Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Neuraminidase Inhibitors Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Neuraminidase Inhibitors Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Neuraminidase Inhibitors Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Neuraminidase Inhibitors Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Neuraminidase Inhibitors Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Neuraminidase Inhibitors Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Neuraminidase Inhibitors Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Neuraminidase Inhibitors Drug Revenue Share by Type (2021-2032) Figure 46. China Neuraminidase Inhibitors Drug Revenue Share by Application (2021-2032) Figure 47. Asia Neuraminidase Inhibitors Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Neuraminidase Inhibitors Drug Revenue Share by Type (2021-2032) Figure 49. Asia Neuraminidase Inhibitors Drug Revenue Share by Application (2021-2032) Figure 50. Asia Neuraminidase Inhibitors Drug Revenue Share by Region (2021-2032) Figure 51. Japan Neuraminidase Inhibitors Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Neuraminidase Inhibitors Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Neuraminidase Inhibitors Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Neuraminidase Inhibitors Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Neuraminidase Inhibitors Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Neuraminidase Inhibitors Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Neuraminidase Inhibitors Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Neuraminidase Inhibitors Drug Revenue Share by Type (2021-2032) Figure 59. SAMEA Neuraminidase Inhibitors Drug Revenue Share by Application (2021-2032) Figure 60. SAMEA Neuraminidase Inhibitors Drug Revenue Share by Country (2021-2032) Figure 61. Brazil Neuraminidase Inhibitors Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Neuraminidase Inhibitors Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Neuraminidase Inhibitors Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Neuraminidase Inhibitors Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Neuraminidase Inhibitors Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Neuraminidase Inhibitors Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Neuraminidase Inhibitors Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Neuraminidase Inhibitors Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Neuraminidase Inhibitors Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Neuraminidase Inhibitors Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Neuraminidase Inhibitors Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Oseltamivir
  • Laninamivir
  • Peramivir
  • Zanamivir
Applications
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
  • Others
Companies covered
  • Teva
  • Roche
  • Pfizer
  • GSK
  • AstraZeneca
  • Sun Pharmaceutical
  • Gilead Sciences
  • Daiichi Sankyo
  • Bristol-Myers Squibb

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Neuraminidase Inhibitors Drug Market by Type
  3. 1.2.1 Global Neuraminidase Inhibitors Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Oseltamivir
  5. 1.2.3 Laninamivir
  6. 1.2.4 Peramivir
  7. 1.2.5 Zanamivir
  8. 1.3 Neuraminidase Inhibitors Drug Market by Application
  9. 1.3.1 Global Neuraminidase Inhibitors Drug Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospital Pharmacy
  11. 1.3.3 Online Pharmacy
  12. 1.3.4 Retail Pharmacy
  13. 1.3.5 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Neuraminidase Inhibitors Drug Market Dynamics
  1. 2.1 Neuraminidase Inhibitors Drug Industry Trends
  2. 2.2 Neuraminidase Inhibitors Drug Industry Drivers
  3. 2.3 Neuraminidase Inhibitors Drug Industry Opportunities and Challenges
  4. 2.4 Neuraminidase Inhibitors Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Neuraminidase Inhibitors Drug Market Perspective (2021-2032)
  2. 3.2 Global Neuraminidase Inhibitors Drug Growth Trends by Region
  3. 3.2.1 Global Neuraminidase Inhibitors Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Neuraminidase Inhibitors Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global Neuraminidase Inhibitors Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Neuraminidase Inhibitors Drug Revenue by Players
  2. 4.1.1 Global Neuraminidase Inhibitors Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global Neuraminidase Inhibitors Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Neuraminidase Inhibitors Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Neuraminidase Inhibitors Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Neuraminidase Inhibitors Drug Key Players Headquarters & Area Served
  7. 4.4 Global Neuraminidase Inhibitors Drug Players, Product Type & Application
  8. 4.5 Global Neuraminidase Inhibitors Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Neuraminidase Inhibitors Drug Market CR5 and HHI
  11. 4.6.3 2025 Neuraminidase Inhibitors Drug Tier 1, Tier 2, and Tier 3
5 Neuraminidase Inhibitors Drug Market Size by Type
  1. 5.1 Global Neuraminidase Inhibitors Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Neuraminidase Inhibitors Drug Revenue by Type (2021-2032)
  3. 5.3 Global Neuraminidase Inhibitors Drug Revenue Market Share by Type (2021-2032)
6 Neuraminidase Inhibitors Drug Market Size by Application
  1. 6.1 Global Neuraminidase Inhibitors Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Neuraminidase Inhibitors Drug Revenue by Application (2021-2032)
  3. 6.3 Global Neuraminidase Inhibitors Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Teva
  2. 7.1.1 Teva Company Information
  3. 7.1.2 Teva Business Overview
  4. 7.1.3 Teva Neuraminidase Inhibitors Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Teva Neuraminidase Inhibitors Drug Product Portfolio
  6. 7.1.5 Teva Recent Developments
  7. 7.2 Roche
  8. 7.2.1 Roche Company Information
  9. 7.2.2 Roche Business Overview
  10. 7.2.3 Roche Neuraminidase Inhibitors Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Roche Neuraminidase Inhibitors Drug Product Portfolio
  12. 7.2.5 Roche Recent Developments
  13. 7.3 Pfizer
  14. 7.3.1 Pfizer Company Information
  15. 7.3.2 Pfizer Business Overview
  16. 7.3.3 Pfizer Neuraminidase Inhibitors Drug Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Pfizer Neuraminidase Inhibitors Drug Product Portfolio
  18. 7.3.5 Pfizer Recent Developments
  19. 7.4 GSK
  20. 7.4.1 GSK Company Information
  21. 7.4.2 GSK Business Overview
  22. 7.4.3 GSK Neuraminidase Inhibitors Drug Revenue and Gross Margin (2021-2026)
  23. 7.4.4 GSK Neuraminidase Inhibitors Drug Product Portfolio
  24. 7.4.5 GSK Recent Developments
  25. 7.5 AstraZeneca
  26. 7.5.1 AstraZeneca Company Information
  27. 7.5.2 AstraZeneca Business Overview
  28. 7.5.3 AstraZeneca Neuraminidase Inhibitors Drug Revenue and Gross Margin (2021-2026)
  29. 7.5.4 AstraZeneca Neuraminidase Inhibitors Drug Product Portfolio
  30. 7.5.5 AstraZeneca Recent Developments
  31. 7.6 Sun Pharmaceutical
  32. 7.6.1 Sun Pharmaceutical Company Information
  33. 7.6.2 Sun Pharmaceutical Business Overview
  34. 7.6.3 Sun Pharmaceutical Neuraminidase Inhibitors Drug Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Sun Pharmaceutical Neuraminidase Inhibitors Drug Product Portfolio
  36. 7.6.5 Sun Pharmaceutical Recent Developments
  37. 7.7 Gilead Sciences
  38. 7.7.1 Gilead Sciences Company Information
  39. 7.7.2 Gilead Sciences Business Overview
  40. 7.7.3 Gilead Sciences Neuraminidase Inhibitors Drug Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Gilead Sciences Neuraminidase Inhibitors Drug Product Portfolio
  42. 7.7.5 Gilead Sciences Recent Developments
  43. 7.8 Daiichi Sankyo
  44. 7.8.1 Daiichi Sankyo Company Information
  45. 7.8.2 Daiichi Sankyo Business Overview
  46. 7.8.3 Daiichi Sankyo Neuraminidase Inhibitors Drug Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Daiichi Sankyo Neuraminidase Inhibitors Drug Product Portfolio
  48. 7.8.5 Daiichi Sankyo Recent Developments
  49. 7.9 Bristol-Myers Squibb
  50. 7.9.1 Bristol-Myers Squibb Company Information
  51. 7.9.2 Bristol-Myers Squibb Business Overview
  52. 7.9.3 Bristol-Myers Squibb Neuraminidase Inhibitors Drug Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Bristol-Myers Squibb Neuraminidase Inhibitors Drug Product Portfolio
  54. 7.9.5 Bristol-Myers Squibb Recent Developments
8 North America
  1. 8.1 North America Neuraminidase Inhibitors Drug Revenue (2021-2032)
  2. 8.2 North America Neuraminidase Inhibitors Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America Neuraminidase Inhibitors Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America Neuraminidase Inhibitors Drug Revenue by Type (2027-2032)
  5. 8.3 North America Neuraminidase Inhibitors Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America Neuraminidase Inhibitors Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America Neuraminidase Inhibitors Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America Neuraminidase Inhibitors Drug Revenue by Application (2027-2032)
  9. 8.5 North America Neuraminidase Inhibitors Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America Neuraminidase Inhibitors Drug Revenue by Country
  11. 8.6.1 North America Neuraminidase Inhibitors Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Neuraminidase Inhibitors Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America Neuraminidase Inhibitors Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Neuraminidase Inhibitors Drug Revenue (2021-2032)
  2. 9.2 Europe Neuraminidase Inhibitors Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe Neuraminidase Inhibitors Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe Neuraminidase Inhibitors Drug Revenue by Type (2027-2032)
  5. 9.3 Europe Neuraminidase Inhibitors Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe Neuraminidase Inhibitors Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe Neuraminidase Inhibitors Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe Neuraminidase Inhibitors Drug Revenue by Application (2027-2032)
  9. 9.5 Europe Neuraminidase Inhibitors Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe Neuraminidase Inhibitors Drug Revenue by Country
  11. 9.6.1 Europe Neuraminidase Inhibitors Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Neuraminidase Inhibitors Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe Neuraminidase Inhibitors Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Neuraminidase Inhibitors Drug Revenue (2021-2032)
  2. 10.2 China Neuraminidase Inhibitors Drug Revenue by Type (2021-2032)
  3. 10.2.1 China Neuraminidase Inhibitors Drug Revenue by Type (2021-2026)
  4. 10.2.2 China Neuraminidase Inhibitors Drug Revenue by Type (2027-2032)
  5. 10.3 China Neuraminidase Inhibitors Drug Revenue Share by Type (2021-2032)
  6. 10.4 China Neuraminidase Inhibitors Drug Revenue by Application (2021-2032)
  7. 10.4.1 China Neuraminidase Inhibitors Drug Revenue by Application (2021-2026)
  8. 10.4.2 China Neuraminidase Inhibitors Drug Revenue by Application (2027-2032)
  9. 10.5 China Neuraminidase Inhibitors Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Neuraminidase Inhibitors Drug Revenue (2021-2032)
  2. 11.2 Asia Neuraminidase Inhibitors Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia Neuraminidase Inhibitors Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia Neuraminidase Inhibitors Drug Revenue by Type (2027-2032)
  5. 11.3 Asia Neuraminidase Inhibitors Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia Neuraminidase Inhibitors Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia Neuraminidase Inhibitors Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia Neuraminidase Inhibitors Drug Revenue by Application (2027-2032)
  9. 11.5 Asia Neuraminidase Inhibitors Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia Neuraminidase Inhibitors Drug Revenue by Country
  11. 11.6.1 Asia Neuraminidase Inhibitors Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Neuraminidase Inhibitors Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia Neuraminidase Inhibitors Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Neuraminidase Inhibitors Drug Revenue (2021-2032)
  2. 12.2 SAMEA Neuraminidase Inhibitors Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Neuraminidase Inhibitors Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Neuraminidase Inhibitors Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA Neuraminidase Inhibitors Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Neuraminidase Inhibitors Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Neuraminidase Inhibitors Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Neuraminidase Inhibitors Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA Neuraminidase Inhibitors Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Neuraminidase Inhibitors Drug Revenue by Country
  11. 12.6.1 SAMEA Neuraminidase Inhibitors Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Neuraminidase Inhibitors Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Neuraminidase Inhibitors Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst